• SwiftPharma and Medace sign strategic collaboration agreement for biomanufacturing and purification of promising medicinal proteins.

    Wednesday September 27th 2023

  • Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen

    Wednesday September 27th 2023

  • argenx announces positive CHMP opinion for subcutaneous efgartigimod for generalized myasthenia gravis

    Friday September 15th 2023

  • SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV

    Friday September 8th 2023

  • SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure

    Friday September 1st 2023

  • Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

    Tuesday August 29th 2023

  • ViroVet achieves groundbreaking results with antiviral drug against BVD

    Monday August 28th 2023

  • argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy

    Monday July 17th 2023

  • Your news here?

  • Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSRĀ® 2.0 for treatment of congestive heart failure

    Monday July 10th 2023

  • argenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy

    Tuesday June 20th 2023

  • Mithra announces new positive preclinical data from CSF-1R inhibitor program

    Thursday June 15th 2023

Strategic Partners